Amphastar Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Amphastar Pharmaceuticals generated cash of $183,503,000, which is more than the previous year. Cash used in financing activities reached the amount of $454,093,000 last year. Net change in cash is therefore -$11,802,000.
Cash Flow
| 2014 | 21.05M | -39.77M | 32.11M |
|---|---|---|---|
| 2015 | 10.68M | -16.92M | 2.23M |
| 2016 | 38.56M | -39.50M | 7.14M |
| 2017 | 39.20M | -38.75M | -7.71M |
| 2018 | 38.19M | -42.18M | 25.00M |
| 2019 | 41.76M | -50.52M | -3.78M |
| 2020 | 57.26M | -36.41M | -2.24M |
| 2021 | 97.99M | -28.67M | -37.01M |
| 2022 | 89.18M | -32.77M | -26.43M |
| 2023 | 183.50M | -649.11M | 454.09M |
AMPH Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 156.33M | 126.58M | 94.50M | 75.55M | 88.20M | 67.45M | 72.35M | 66.07M | 67.82M | 53.58M |
Operating activities | ||||||||||
Net income | 137.54M | 91.38M | 63.30M | 1.09M | 46.50M | -6.66M | 4.50M | 10.53M | -2.78M | -10.69M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 41.77M | 28.74M | 26.75M | 25.18M | 21.12M | 16.51M | 15.43M | 14.56M | 13.25M | 14.44M |
Stock-based compensation expense | 20.24M | 17.86M | 18.68M | 20.49M | 17.29M | 0 | 17.08M | 15.12M | 12.81M | 9.28M |
| Deferred income tax benefit | 20.24M | 17.86M | 18.68M | 20.49M | 17.29M | 0 | 17.08M | 15.12M | 12.81M | 9.28M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -26.08M | -10.13M | -14.92M | -20.16M | 6.70M | -16.29M | -8.10M | 6.37M | -11.01M | 1.21M |
Inventories | -1.72M | -11.74M | 1.25M | 15.29M | -41.10M | -5.98M | 18.65M | -9.71M | 9.77M | 6.56M |
Accounts payable | 13.23M | -736K | 3.01M | 14.96M | -17.93M | 29.15M | 6.68M | -823K | -3.13M | 5.5M |
Cash generated by operating activities | 183.50M | 89.18M | 97.99M | 57.26M | 41.76M | 38.19M | 39.20M | 38.56M | 10.68M | 21.05M |
Investing activities | ||||||||||
Purchases Of Investments | -144.55M | -35.76M | -17.37M | -13.55M | -8.81M | -308K | -5.64M | -3.60M | 0 | 0 |
Investments In Property Plant And Equipment | -38.16M | -24.03M | -27.45M | -33.85M | -41.55M | -46.80M | -35.09M | -21.38M | -16.04M | -20.49M |
Acquisitions Net | -506.40M | 421K | 0 | 0 | 0 | 4.64M | 2M | -12.46M | 51K | -18.35M |
Cash generated by investing activities | -649.11M | -32.77M | -28.67M | -36.41M | -50.52M | -42.18M | -38.75M | -39.50M | -16.92M | -39.77M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 15.92M | 23.16M | 18.29M | 38.03M | 0 | 0 | 0 | 38.01M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -58.14M | -39.90M | -28.87M | -24.42M | -22.29M | -25.04M | -30.74M | -9.90M | -9.86M | -734K |
Repayments of term debt | 526.34M | -1.78M | -37.90M | -8.40M | -3.21M | -5.70M | 9.27M | -4.45M | -2.20M | -54.21M |
Cash used in financing activities | 454.09M | -26.43M | -37.01M | -2.24M | -3.78M | 25.00M | -7.71M | 7.14M | 2.23M | 32.11M |
Net Change In Cash | -11.80M | 29.74M | 32.08M | 18.95M | -12.65M | 20.74M | -6.76M | 6.28M | -1.75M | 14.24M |
Cash at end of period | 144.53M | 156.33M | 126.58M | 94.50M | 75.55M | 88.20M | 65.59M | 72.35M | 66.07M | 67.82M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |